Tıkayıcı koroner arter hastalarında serum IGF-I düzeyi ve bazı parametrelerle ilişkisi

Amaç: Tıkayıcı koroner hastalarında serum IGF-I ile total protein, albumin, ürik asit, trigliserit, total kolesterol, HDL-Kolesterol, yaş, VKİ (vücut kütle indeksi), bel-kalça oranı (BKO) ve bel ölçüsü (BÖ) arasındaki ilişkiyi belirlemek. Yöntem: Çalışmada efor testi negatif olan 12 vaka (7 erkek, 5 kadın) kontrol, efor testi pozitif ve tıkayıcı koroner stenozu >% 50 olan 12 vaka (7 erkek, 5 kadın) ise deneme grubu olarak alındı. Bulgular: Deneme grubunda IGF-I düzeyi (122±47.43 ng/ml) kontrol grubuna göre (180±48.15 ng/ml) düşüktü. Erkeklerde IGF-I düzeyi deneme grubunda (124.5±43.07 ng/ml) kontrol grubundan (185.5±56.68 ng/ml) düşük iken; kadınlarda IGF-I düzeyi yönünden deneme (118.1±58.09 ng/ml) ve kontrol (185.5±56.68 ng/ml) grupları arasındaki fark önemsizdi. Deneme grubunda IGF-I ile HDL-kolesterol arasında pozitif korelasyon gözlendi. Ürik asit, trigliserit, total kolesterol ve HDL-kolesterol düzeyleri yönünden deneme ve kontrol grupları arasında önemli fark yoktu. Albumin düzeyleri, total deneme grubunda ve erkeklerde kontrol grubuna göre düşük bulundu. Sonuç: KAH ile ilişkiler yönünden ve GH’nun yanında IGF-I’in de lipid düzeylerinin regülasyonlarında yer alabileceğinin belirtisi olabilmesi açısından önemli bir sonuç olduğu kanaatine varıldı.

The relationships between serum IGF-I (insulin like growth factor-I) levels and some biochemical parameters in the patients with obstructive coronary artery disease

Objective: To investigate the relationships between levels IGF-I and levels of total protein, albumin, uric acid, triglyceride, total cholesterol, HDL-cholesterol, age, WHR (waist-hip ratio), BMI (body mass index), the measurement of waist in the patients with obstructive coronary artery disease. Methods:12 people (7 male, 5 female) with presence of negative exercise test as a control group and 12 people (7 male, 5 female) with presence of pozitive exercise test, obstructive coroner stenoses >50% as a test group were included. Results: In the test group IGF-I levels (122±47.43 ng/ml) were significantly lower than the control group (180±48.15 ng/ml). Also, the measurement of IGF-I levels in male test group (124.5±43.07 ng/ml) were significantly lower than the control group (185.5±56.68 ng/ml). In test group of female, IGF-I levels were (118.1±58.09 ng/ml) also lower than the levels in control group (172.1±37.75 ng/ml), but not significantly. In test group the pozitive correlations between IGF-I and HDL-cholesterol were found. Uric acid, triglyceride, total cholesterol and HDL-cholesterol levels were similarly in test and control groups, but in total and male test groups the levels of albumin were lower than the control groups. Conclusion: IGF-I may be important in relations with CAD and a sign of taking a place in regulation of lipid levels along with GH.

___

  • Clemmons DR, Underwood LE. Role of ınsulin like growth factors and growth hormone in reversing catabolic states, Horm Res 1992;38:37-40.
  • Siddle K, Soos MA, Field CE, Nave BT. Hybrid and atypical insulin /insulin like growth factor I receptors. Horm Res 1994;41:56-65.
  • Whitley RJ, Meikle AW, Watts NB. Pituitary function In: Burtis CA, Ashwood ER, eds. Tietz fundamentals of clinical chemistry. 4th Ed.. Philadelphia: Saunders; 1996. p.626-39.
  • Chang TC, Chang CC, Tsai KS, Huang TS, Tsai WY, Lin MH, et al. Clinical experience of octreotide in the treatment of acromegaly. J Formos Med Assoc 1992;91:595-600.
  • Sacca L, Cittadini A, Fazio S. Growth hormone and heart, Endocrine Rev 1994;15:555-73.
  • Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995;30:825-34.
  • Spallarossa P, Brunelli C, Minuto F, Caruso D, Battistini M, Caponnetto S et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996;77:200-202.
  • Botker HE, Skjaerbaek C, Eriksen UH, Schmitz O, Orskov H. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm and syndrome X. Am J Cardiol 1997;79:961-63.
  • Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I and IGFBP-1 levels in an elderly population:relation to cardiovascular risk factors and disease, Arterioscler Thromb Vasc Biol 1998;18:277-82.
  • Fuller SJ, Mynett JR, Sugden PH . Stimulation of cardiac protein synthesis by insulin like growth factors. Biochem J 1992;282:85-90.
  • Scheinowitz M, Abramov D, Eldar M. The role of insulin-like and basic fibroblast growth factors on ischemic and infarcted myocardium:a mini review. Int J Cardiol 1997;59:1-5.
  • Olivecrona H, Ericsson S,Berlund L, Angelin B . Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment. Br Med J 1993;306:1726-7.
  • Dahlen GH. Lp (a) in cardiovascular disease. Atherosclerosis 1994;108:11-26.
  • Friedman Rb,Young DS. Effects of Disease on clinical laboratory tests. 3rd Ed. Washıngton: AACC Press; 1997.
  • Mendenhall CL, Roselle GA, Grossman CJ, Gartside P. I:The effects of recombinant human insulin like growth factor-1 on nutritional recovery in the malnourished alcoholic rat, II:The effects of recombinant human insulin like growth factor-I on immunological recovery in the malnourished alcoholic rat, Alcohol Clin Exp Res 1997;9:1676-89.
  • Chaitman B. Exercise stress testing In: Braunwald E, ed. A textbook of cardiovascular medicine, heart disease. 4th Ed. Philadelphia: Saunders;1992. p.166.
  • Gaudet D, Vohl MC, Perron P, Tremblay G, Gagne C, Lesiege D et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998;97:871-7.
  • Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reapprasial of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, adrenal disease Am J Kidney Dis 1999;33:225-34.
  • Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al . Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996;20:975-80.
  • Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V et al . Lipoprotein (a) and coronary heart disease risk:a nested case control study of the Helsinki Heart Study Participants. Atherosclerosis 1991;89:59-67.
  • Ridker PM, Hennekens CH,Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
  • Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M . Lp (a) Lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199-204.
  • Canbulat EC, Türkalp I. Acute myocardial infarction risk predicted by serum levels of lipoprotein (a) Turkish population. Marmara Medical J 1994;7:69-73.
  • Gamble G, MacMahon S, Culpan A, Ciobo C, Whalley G, Sharpe N . Atherosclerosis and left ventricular hypertropy:persisting problems in treated hypertensive patients. J Hypertens 1998;16:1389-95.
  • Roberts WC . Atherosclerotic risk factors-Are there ten or is there only one? Am J Cardiol. 1989;64:552-4.
  • Pergola De G, Giorgino F, Cospite MR, Giagulli VA, Cignarelli M,Ferri G et al. relation between sex hormones and serum lipoprotein and lipoprotein (a) concentrations in premenopausal obese women. Arterioscler Thromb 1993;13;675-9.
  • Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA et al. Serum insulin like growth factor 1 in a random population sample of men and women:relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol1994;41:351-7.